Constitution of HORUS cohort

WP1 will constitute two cohorts of solid organ transplant recipients with comprehensive clinical, characterization and biobanking of samples for further analyses by WP2 to 4.

Improving our understanding of CMV-specific immune dysfunctionality in the context of immunosuppression

To obtain insight into the underlying mechanisms/pathways of dysfunction and identify clear signatures of dysfunctionality at day 0 of transplantation and at day 0 of infection.

Improving our understanding of CMV-specific immune response in a naïve individual in the context of immunosuppression

To obtain insight into the events occurring before CMV-infection and into the very early mechanisms/pathways leading to CMV control in naïve immunocompromised patients, which can be related to either the absence of CMV transmission from the graft and/or of a fast/efficient anti-CMV immune response.

Validation of immune markers associated to CMV infection, associated to poor outcomes during CMV infection and associated to long-term outcomes

Thanks to results of WP2 and WP3, we aim to extrapolate the signature found for R+ and for D+R- patients to the whole cohort in the scenario before infection and at the beginning of infection.

Methods to improve the activation of immune cells in the context of immunosuppression

Develop in vitro, mouse, and clinical models using WP2-3 findings to enhance CMV immune response through targeted immune modulation.

Project, data & IP Management

Ensure effective leadership through strategic coordination, data management, compliance monitoring, and administrative milestone fulfillment.

Maximizing HORUS outcomes and impacts

Enhance impact by executing the HORUS dissemination and exploitation plan, maintaining related agreements, and addressing regulatory barriers through proposals to public bodies.